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ComplementFlaviviruses are a group of ~70 small RNA viruses responsible for signiﬁcant morbidity and mortality across
the globe. Efforts to develop effective vaccines for several clinically important ﬂaviviruses are underway.
Antibodies are a signiﬁcant component of the host's protective response against ﬂavivirus infection with the
potential to contribute to immunity via several distinct mechanisms, including an ability to directly neutralize
virus infection. Conversely, virus-reactive antibodies have been implicated in the increased risk of severe
clinical manifestations following secondary dengue virus infection. In this review, we will discuss recent
progress toward understanding the molecular basis of antibody-mediated neutralization of ﬂaviviruses.
Neutralization requires engagement of the virion with a stoichiometry that exceeds a required threshold.
From this perspective, we will discuss viral and host factors that impact the number of antibody molecules
bound to the virus particle and signiﬁcantly modulate the potency of neutralizing antibodies.Laboratory of Viral Diseases,
, Room 1E19A.2, Bethesda, MD
).
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Antibodies are glycoproteins that equip the adaptive humoral
immune system with the capacity to recognize a constantly evolving
spectrum of pathogens. A signiﬁcant role for antibodies in protectionof the host from virus infection has been established (reviewed in
Parren and Burton, 2001). Antibodies exert their antiviral effects by
virtue of a capacity to bind viruses and directly neutralize infectivity,
as well as via effector functions coordinated by the crystallizable
fragment (Fc) region of the antibody heavy chain (Burton, 2002;
Nimmerjahn and Ravetch, 2008). Passive transfer of virus-reactive
antibody or immune sera has been shown to confer protection from
infection by many virus types (reviewed in Parren and Burton, 2001;
Roehrig et al., 2001; Sawyer, 2000). These ﬁndings highlight the
general importance of humoral immunity to virus infection, and may
Fig. 1. Structure of the ﬂavivirus E protein and its arrangement on the virion. A) Ribbon
diagram of the anti-parallel ﬂavivirus E protein dimer as seen from the top and side.
Individual domains of the E protein are indicated, as is the fusion loop at the distal end
of E-DII. The N-linked carbohydrate modiﬁcations on E are shown as brown spheres.
B) Cryoelectron reconstruction of the ﬂavivirus immature virion. Image was created
using Chimera (http://www.cgl.ucsf.edu/chimera/). C) Cryoelectron reconstruction of
the ﬂavivirus mature virion illustrating the arrangement of E proteins in a T=3 pseudo-
icosahedron. Individual E proteins are colored according to their proximity to the 2-, 3-,
or 5-fold symmetry axes (blue, red, and green, respectively).
Image obtained from the VIPERdb Virus Particle Explorer (http://viperdb.scripps.edu/)
(Shepherd et al., 2006).
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antibody response to be targeted by vaccination.
Flaviviruses are a group of positive-stranded RNA viruses capable
of signiﬁcant morbidity and mortality that are transmitted to humans
primarily by arthropod vectors (Lindenbach et al., 2007). Highly-
effective vaccines for several ﬂaviviruses are in use, including yellow
fever virus (YFV) (Barrett and Teuwen, 2009), tick-borne encephalitis
virus (TBEV) (Heinz et al., 2007), and Japanese encephalitis virus
(JEV) (Halstead and Thomas, 2010). A vaccine to protect against
dengue virus (DENV) is not yet available despite an urgent need (N50
million human infections annually) and considerable effort by the
public and private sectors (Guy et al., 2010; Whitehead et al., 2007).
DENV vaccine development is complicated considerably by a
perceived need to simultaneously protect against the four serotypes
of DENV that circulate in nature, and the possibility that a non-
protective humoral response may contribute to more severe clinical
outcomes in vaccinated populations (Whitehead et al., 2007).
Flavivirus-reactive antibodies may be protective or pathogenic
depending on circumstances and context (Halstead, 2003). In this
regard, understanding the breadth, speciﬁcity, and functional prop-
erties of the polyclonal antibody response to infection and vaccination
will contribute signiﬁcantly to the development of safe vaccines
against ﬂaviviruses.
A reductionist approach toward understanding how antibodies
contribute to protection from ﬂaviviruses considers how their
neutralizing activity is controlled at the level of binding to individual
virions and in what numbers (Burton et al., 2001; Della-Porta and
Westaway, 1978). This stoichiometric viewpoint serves as an
interesting reference from which to consider the impact of cellular
factors and viral dynamics on antibody-mediated neutralization.Flaviviruses are complex antigens
Flaviviruses are small spherical virus particles composed of three
structural proteins (capsid, envelope, and pre-membrane/mem-
brane), an RNA genome, and a lipid envelope (Mukhopadhyay et al.,
2005). The envelope (E) protein is a type II viral fusion protein
composed of three distinct domains connected to the viral membrane
by a helical structure called the stem anchor (Fig. 1A) (reviewed in
Harrison, 2008). The E protein orchestrates the processes of virus
assembly, budding, and entry into target cells. This protein is also the
primary target of neutralizing antibodies; all three E protein domains
contain epitopes recognized by antibodies capable of neutralizing
infection under some circumstances (reviewed in Roehrig, 2003).
Flaviviruses bud into the endoplasmic reticulum as immature virions
on which the E proteins interact with the pre-membrane (prM)
protein as heterotrimeric spikes arranged with icosahedral symmetry
(Fig. 1B) (Zhang et al., 2003; Zhang et al., 2007). Interactions between
the prM and E proteins prevent fusion of the virus with membranes of
the producer cell during egress through acidic compartments of the
secretory pathway (Guirakhoo et al., 1991; Heinz et al., 1994).
Cleavage of prM by the cellular protease furin during transit through
the Golgi network is a required step in the viral lifecycle that deﬁnes
the transition from an immature non-infectious virus particle into an
infectious form (Elshuber et al., 2003). The products of cleavage are a
~8 kDa M protein that remains associated with the virion, and a “pr”
portion that disassociates from the virus particle upon release from
the cell (Li et al., 2008; Yu et al., 2008), although as discussed below in
greater detail, this cleavage event is often inefﬁcient and results in the
release of infectious virions that retain some uncleaved prM
molecules. While prM-speciﬁc antibodies display limited neutralizing
activity (Aaskov et al., 1988; Beltramello et al., 2010; Kaufman et al.,
1989; Vazquez et al., 2002), it has been suggested that they contribute
to the pathogenesis of DENV virus infection (Dejnirattisai et al., 2010;
Rodenhuis-Zybert et al., 2010).Mature ﬂaviviruses incorporate 180 copies of the E protein
arranged as anti-parallel dimers in an unusual herringbone pseudo-
icosahedral symmetry pattern (Kuhn et al., 2002; Mukhopadhyay et
al., 2003). In this conﬁguration the E protein exists in three distinct
chemical environments deﬁned by proximity to the three different
symmetry axes of the virion (Fig. 1C). This dense arrangement of E
proteins adds considerably to the complexity of the antigenic surface
of the virion as epitopes may be differentially accessible for antibody
binding depending on their position on the virus particle (Kaufmann
et al., 2006; Kaufmann et al., 2010; Nybakken et al., 2005).
Models of the stoichiometric requirements for antibody-mediated
neutralization
Considering how the number of antibody molecules bound to the
viriondetermineswhether or not virus neutralization occurs is a useful
framework to explore factors that govern antibody potency. Two
models to explain the behavior of neutralizing antibodies have been
proposed and debated extensively. An excellent historical perspective
of both schools of thought is provided by Parren and Burton (2001).
“Single-hit” concepts of neutralization postulate that neutraliza-
tion occurs when the virion is bound by antibody at a “critical site”
(Dulbecco et al., 1956). This model posits that antibody binding to
functionally important locations on the virion is sufﬁcient to disrupt
required steps of the virus entry process and irreversibly inactivate
virions (Mandel, 1976). In this regard, not all binding events are
equivalent and antibodies bound to non-critical sites on the virion do
not contribute to neutralization. Experiments demonstrating that
neutralization proceeds via ﬁrst order kinetics have been used to
support this perspective, and suggest neutralization begins immedi-
ately after exposure to antibody (Dulbecco et al., 1956). However,
interpretation of these results is somewhat controversial. The inability
to observe a lag phase in kinetic neutralization experiments,
corresponding to the time required to load virions with multiple
antibody molecules, may simply reﬂect limitations of experimental
308 K.A. Dowd, T.C. Pierson / Virology 411 (2011) 306–315conditions (discussed in Della-Porta and Westaway, 1978). Further-
more, the implied requirement that coordinated events across the
virus particle during virus entry may be inhibited by a single binding
event is difﬁcult to envision in light of the diversity of virus structures
and methods for penetrating host cells.
A “multiple-hit” requirement suggests that neutralization occurs
when an individual virion is bound by antibody with a stoichiometry
that exceeds a required threshold, and is reversible (Burnet et al.,
1937) (reviewed by Parren and Burton, 2001). Neutralization can
therefore be considered from a reductionist perspective focused on
the number of antibodies bound to the virion during critical steps of
the virus entry process. A review of data supporting a multiple-hit
mechanism of neutralization of ﬂaviviruses is provided by Della-Porta
and Westaway (1978). Evidence consistent with this perspective
discussed within includes: i.) the epitope occupancy requirements for
neutralization of ﬂaviviruses, ii.) an estimate of the stoichiometric
requirements for neutralization, iii.) the existence of a fraction ofFig. 2. Antibody afﬁnity and epitope accessibility govern the neutralization potency of anti-ﬂa
by antibody with a stoichiometry that exceeds a threshold (estimated as 30 mAbs based on s
virion with a stoichiometry below this threshold may support antibody-dependent enhanc
bound by antibody at any non-saturating concentration. For example, incubation of a theoret
Kd results in engagement of the virion with a stoichiometry of an average of 90 antibody m
engagement by 60 antibodies, as determined by the relationship (Bound/Boundmax)=([A
interactions, such as the single T330I substitution introduced into the WNV E protein. B
theoretical ﬂavivirus displaying 180 epitopes, an epitope occupancy of 17% is required to
accessibility translates into increases in the fraction of epitopes that must be engaged in orde
for antibodies that bind structurally distinct epitopes on the ﬂavivirus. Antibodies that bind
occupancy (60%, green shading), whereas antibodies that bind poorly accessible structures
Figures and data were modiﬁed from (Pierson et al., 2008; Pierson et al., 2007).viruses resistant to neutralization at any concentration of antibody,
iv.) the phenomenon of antibody-dependent enhancement of infec-
tion, and v.) the augmented neutralizing activity of anti-ﬂavivirus
antibodies in the presence of complement.
Antibody afﬁnity controls the percentage of viral epitopes bound
by antibody
At least two factors deﬁne conditions that allow engagement of
virions by antibody with a stoichiometry that exceeds the threshold
requirements for neutralization. One of these factors, antibody afﬁnity,
deﬁnes the fraction of epitopes bound by antibody molecules at any
particular concentration (Klasse and Sattentau, 2002). For example,
incubation of a virion that displays 180 epitopes with antibody at a
concentration equal to its Kd will result in occupancy of virus particles
with an average of 90 antibody molecules (Fig. 2A). Thus, it is not
surprising that in many instances, antibody afﬁnity correlates withvivirus antibodies. Neutralization of ﬂavivirus virions requires engagement of the virion
tudies with twoWNV E-DIII-LR-speciﬁc mAbs) (Pierson et al., 2007). Engagement of the
ement of infection (ADE). A) Antibody afﬁnity determines the percentage of epitopes
ical virus displaying 180 E protein epitopes with antibody at a concentration equal to its
olecules. Reducing the concentration two-fold (0.5× of the antibody Kd) translates into
b]/([Ab]+Kd)). (Right panel) Mutations that change the afﬁnity of antibody–virion
) Epitope accessibility governs the occupancy requirements for neutralization. For a
exceed a stoichiometric threshold of 30 antibody molecules. A reduction in epitope
r to support virus neutralization. (Right panel) Epitope accessibility varies considerably
highly accessible determinants my completely neutralize infection at relatively modest
neutralize infection only at full occupancy (100%, red shading).
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bodies that bind viral antigens via high afﬁnity interactions will dock
onto the virion in greater numbers than those that bind with low-
afﬁnity to the same epitope. In this regard, vaccination strategies that
elicit high-afﬁnity antibodies are desirable, as this translates into
increased neutralization at lower concentrations of antibody. Converse-
ly, antigenic variants that reduce the strength of antibody binding are
less sensitive to neutralization as a functionof reduced occupancy at any
non-saturating concentration of antibody. For example, the recent
demonstration that genotypic variation of DENV reduces the neutral-
izing activity of antibodies against heterologous strains of the same
DENV serotype can be explained by differences in antibody afﬁnity
(Brien et al., 2010; Sukupolvi-Petty et al., 2010; Wahala et al., 2010).
Epitope accessibility is a critical and dynamic factor that governs
antibody-mediated neutralization of viruses
Not all antibodies that bind virions with high afﬁnity are
characterized by signiﬁcant neutralizing activity. For example,
monoclonal antibodies (mAbs) E16 and E53, described in detail
below, bind structurally distinct epitopes on the West Nile virus
(WNV) E protein with high afﬁnity, yet differ in their capacity to
neutralize infection by several orders of magnitude (Nelson et al.,
2008; Oliphant et al., 2005; Oliphant et al., 2006; Pierson et al., 2007).
Antibody afﬁnity determines the fractional occupancy of epitopes on
the surface of the virion, not the number of antibody molecules bound
to the virion under any condition. Thus, insight into the afﬁnity of
antibody–virion interactions is not sufﬁcient to predict whether a
particular antibody can exceed the stoichiometric requirements for
neutralization. The stoichiometry of antibody binding is determined
both by antibody afﬁnity and by the total number of epitopes on the
virion that are accessible for binding. Epitope accessibility deﬁnes the
occupancy requirements for neutralization (Fig. 2B), which can vary
considerably for antibodies that bind ﬂaviviruses. For example, the
occupancy requirements for neutralization by mAbs speciﬁc for a
type-speciﬁc epitope on E-DIII of DENV serotype 2 (DENV-2) were
markedly lower than the fractional occupancy required for neutral-
ization via adjacent, partially overlapping, group- and sub-complex-
reactive epitopes (Gromowski and Barrett, 2007; Gromowski et al.,
2008; Gromowski et al., 2010). In agreement, the occupancy
requirements for a panel of WNV-reactive mAbs were determined
and varied considerably as a function of the predicted accessibility of
the epitope on the mature virus particle (Pierson et al., 2007). The
widely varying occupancy requirements for neutralization of ﬂavi-
viruses directly support the multiple-hit model. Factors that govern
epitope accessibility and the occupancy requirements of neutraliza-
tion are discussed in the succeeding sections.
Steric constraints arising from virion structure
The dense herringbone arrangement of E proteins on the mature
ﬂavivirus imposes steric constraints on antibody recognition. In fact,
none of the mAbs characterized to date using structural methods are
capable of binding all 180 E proteins incorporated into the virion
(Cherrier et al., 2009; Kaufmann et al., 2006; Kaufmann et al., 2010;
Lok et al., 2008; Nybakken et al., 2005). For example, the neutralizing
mAb E16 binds a discontinuous epitope on the upper lateral ridge of
domain III of the E protein (DIII-LR) (Nybakken et al., 2005; Oliphant
et al., 2005). Cryoelectron microscopic (cryo-EM) reconstructions of
Fab fragments of E16 bound to WNV demonstrate that E16 binds a
maximum of 120 epitopes on the mature virion (Kaufmann et al.,
2006). E16 cannot bind E proteins proximal to the ﬁve-fold symmetry
axis due to steric constraints imposed by the very close proximity of
neighboring DIII molecules (Fig. 1C). Antibody occupancy of a
relatively small fraction (~25%) of the 120 accessible DIII-LR epitopes
is required for neutralization (Fig. 2B) (Pierson et al., 2007).In contrast, many WNV- and DENV-reactive antibodies neutralize
infection only at maximal occupancy, in the presence of saturating
concentrations of antibody. Residues that contribute signiﬁcantly to
antibody binding have been mapped for large panels of ﬂavivirus
mAbs (Beltramello et al., 2010; Brien et al., 2010; Gromowski and
Barrett, 2007; Gromowski et al., 2008, 2010; Kiermayr et al., 2009;
Mandl et al., 1989; Oliphant et al., 2005, 2006; Shrestha et al., 2010;
Sukupolvi-Petty et al., 2010, 2007). Inmany cases, plotting the location
of these residues on the reconstruction of the intact mature virus
particle does not provide a clear structural basis for antibody
recognition due to accessibility considerations. For example, the
highly conserved fusion loop at the top of E domain II (DII-FL)
recognized bymAb E53 is buried betweenDI andDIII of the opposing E
protein of the dimers arranged on the mature virion (Cherrier et al.,
2009;Mukhopadhyay et al., 2005). Antibodies speciﬁc for these poorly
accessible determinants have to bind essentially all of them in order to
exceed the stoichiometric threshold of neutralization (Nelson et al.,
2008; Stiasny et al., 2006). Importantly, many antibodies that can bind
virions display very little in vitro neutralizing activity because
exceeding this threshold is not possible at any concentration of
antibody (Nelson et al., 2008; Oliphant et al., 2006; Pierson et al.,
2007). The limited neutralizing activity of antibodies speciﬁc for the
prM protein may also reﬂect an inability to exceed the threshold
requirements for neutralization.
The impact of structural dynamics
The utility of molecular models of viral proteins and their
organization on virions are powerful tools that reveal the average
state of proteins on the virion. Estimates of epitope accessibility based
on these structural models may be complicated by the possibility that
virions are in constant motion. It is well established that proteins
sample many conformations at equilibrium (reviewed by Boehr and
Wright, 2008). This is also undoubtedly true of proteins incorporated
into virus particles (reviewed in Johnson, 2003; Witz and Brown,
2001). For example, limited proteolysis studies of picornaviruses
suggest the capsids of these viruses “breathe” (Bothner et al., 1998).
Interestingly, a small molecule inhibitor that blocks capsid dynamics
neutralizes infectivity (Lewis et al., 1998). Poliovirus VP4 is recognized
by neutralizing antibodies even though this protein is not predicted to
be accessible on the exterior of the particle (Li et al., 1994), implying
that epitopes transiently and reversibly exposed on virions via
structural dynamics may be stabilized by antibody recognition.
Viral dynamicsmay also have a role in the accessibility of epitopes on
ﬂaviviruses. The mAb 1A1D-2 is a DENV sub-complex speciﬁc mAb that
recognizes an epitope on the A-strand of E-DIII and is capable of
neutralizing DENV serotypes 1, 2, and 3 (Lok et al., 2008; Roehrig et al.,
1998). Analysis of the accessibility of residues involved in 1A1D-2
recognition identiﬁed steric conﬂicts that should prevent binding to DIII
in all three symmetry environments of the mature virus particle,
consistent with an inability to dock Fab fragments of this antibody onto
virions at 4 °C (Lok et al., 2008). Interestingly, antibody binding was
possible when incubations were carried out at 37 °C. Cryo-EM recon-
structions of 1A1D-2 in complex with DENV revealed a marked rotation
of the E proteins away from the surface of the virion as compared to the
arrangement of E proteins in the average state of the mature virion. The
structure of 1A1D-2 bound to DENV provides insight into one of many
potential conformations sampled by DENV at equilibrium, and demon-
strates how such structural changes can modulate epitope accessibility
(Fig. 3). Whether viral dynamics play a more widespread role in
neutralization via other epitopes remains to be determined.
Changes in oligomeric state occurring during virion maturation
Populations of ﬂaviviruses released from infected cells contain not
only immature and mature virions, but also virus particles that share
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required for the production of an infectious particle (Elshuber et al.,
2003), it may be inefﬁcient. In fact, recent studies suggest that as
many as 92% of DENV virions incorporate prM proteins that are not
cleaved during virus egress (Junjhon et al., 2010). At least some of
these partially mature virions remain infectious, although whether
there is a limit to the number of uncleaved prM molecules that an
infectious virionmay retain is unknown (Davis et al., 2006; Guirakhoo
et al., 1992). While the structure of partially mature virions is not yet
known, the E proteins on these heterogeneous virus particles likely
exist as both anti-parallel dimers that lie ﬂat against the viral
membrane (characteristic of mature virions), as well as spikes that
project off the surface of the virion (characteristic of immature
virions). E proteins in these distinct conformations and oligomeric
states present very different surfaces for antibody recognition
(Guirakhoo et al., 1992; Heinz et al., 1994).
Analysis of the neutralization proﬁles of several mAbs speciﬁc for
epitopes predicted to be poorly accessible on the mature virion
revealed a subset of virions resistant to neutralization by saturating
concentrations of antibody (Nelson et al., 2008; Pierson et al., 2007).
A similar pattern was observed when the number of epitopes on the
virion recognized by the potently neutralizing mAb E16 was reduced
using genetic methods, as discussed below (Mehlhop et al., 2009;
Pierson et al., 2007). Increasing the efﬁciency of virus maturation
yielded a homogenous population of mature WNV resistant to
neutralization by mAb E53 and other mAbs speciﬁc for cryptic
determinants (Nelson et al., 2008). Conversely, inhibiting maturation
increased sensitivity to neutralization by these mAbs, and signiﬁ-
cantly reduced the size of the resistant fraction described above.
These results suggest that the process of virion maturation
modulates the sensitivity of WNV to neutralization by mAbs that
recognize several distinct classes of epitopes through changes in
epitope accessibility (Fig. 3C). The structural basis of this phenom-
enon has been conﬁrmed. The mAb E53 binds the highly conserved
fusion loop at the terminus of E-DII (DII-FL) and neutralizes WNV in
a maturation state-dependent fashion. Cryo-EM reconstruction
studies of Fab fragments of E53 bound to WNV and DENV
demonstrated binding to E proteins only when complexed with
prM in the heterotrimeric spikes of immature virions (Cherrier et al.,
2009). In this context, binding to two of three fusion loop epitopes
was possible; binding to the third E protein was prevented by steric
conﬂicts between the DII-FL and prM. Due to the inaccessibility of
the DII-FL epitope on the mature form of the virion (discussed
above), signiﬁcant binding or neutralization of E53 to mature virions
was not detected.Limits on epitope accessibility imposed by the steric bulk of intact
antibody molecules
Antibodies are relatively large molecules that occupy consider-
ably more space than simply the surface area of the virion in contact
with the paratope. This steric bulk is thought to contribute to
neutralization by sterically preventing required interactions with
cellular factors during the virus entry process or by interfering with
conformational changes in viral proteins required for fusion (Klasse
and Sattentau, 2002). In contrast, the size of antibody molecules may
in some instances be detrimental. For example, the broadly
neutralizing mAb 4E10 binds the conserved membrane proximal
external region (MPER) of HIV-1 gp41. Fabs and a smaller
engineered fragment of mAb 4E10 displayed greater neutralizing
activity than the intact antibody molecule, presumably due to a
reduction in the degree of steric occlusion (Klein et al., 2009).
Antibody size may also inﬂuence the maximal number of antibody
molecules that can simultaneously bind to virions (Kiermayr et al.,
2009).Estimates of the stoichiometry of antibody-mediated
neutralization of West Nile virus
The number of antibodies required for the neutralization of several
virus types has been investigated (reviewed in Burton et al., 2001).
The stoichiometric requirement for neutralization varies considerably
among viruses. For example, neutralization of poliovirus occurs
following engagement by 4–5 mAbs, whereas inhibition of rabies
virus requires more than 200 IgG molecules (Flamand et al., 1993;
Icenogle et al., 1983). One unifying principle of antibody-mediated
neutralization is that the number of antibodies required to neutralize
infection is determined by the surface area of the virus particle
(Burton et al., 2001); increased virion size requires a larger number of
antibody molecules to sterically interfere with required steps in the
virus entry process. The stoichiometric requirement for neutralization
of WNV has been studied using two antibodies speciﬁc for the DIII-LR
and was estimated as ~30 antibody molecules (Mehlhop et al., 2009;
Pierson et al., 2007). Estimates for the number of antibodies required
to neutralize WNV are in agreement with the predictions of this
“coating theory” (Klasse and Burton, 2007). However, the functional
signiﬁcance of this number is not presently clear, as the number of
antibodies required for neutralization does not in itself provide insight
into themechanism of neutralization. Antibodies have the potential to
block multiple steps in the virus entry process. Antibodies that block
ﬂavivirus attachment (Crill and Roehrig, 2001; He et al., 1995;
Nybakken et al., 2005) and fusion (Gollins and Porterﬁeld, 1986;
Roehrig et al., 1998; Stiasny et al., 2007; Thompson et al., 2009; Vogt
et al., 2009) have been described, although it is quite possible that
antibodies have the potential to neutralize via multiple mechanisms
depending on epitope occupancy. For example, mAb E16 blocks viral
fusion by preventing the conformational changes in the E protein
required to drive fusion (Kaufmann et al., 2009; Thompson et al.,
2009) and has a modest effect on virus attachment at high
concentrations. These observations suggest that the threshold
requirements for neutralization may differ depending on the step in
the virus entry/fusion pathway blocked by the antibody. Likewise, it
remains to be determined whether the threshold requirements for
neutralization will differ for antibodies speciﬁc for structurally
distinct epitopes, as suggested by studies of mAbs that neutralize
bovine papillomavirus (Booy et al., 1998; Roden et al., 1994). To date,
the analysis of the stoichiometric requirements for antibodies that
bind outside the DIII-LR has been complicated by the signiﬁcant
impact of virion maturation and/or structural dynamics on epitope
accessibility.
Antibody-dependent enhancement of infection
Antibody-dependent enhancement of infection (ADE) describes a
marked increase in the efﬁciency of virus infection in the presence of
non-neutralizing concentrations of virus-reactive antibody (Halstead
and O'Rourke, 1977; Hawkes, 1964). ADE is most commonly observed
using cells expressing Fc- or complement-receptors, and has been
observed in vitro for several viruses (reviewed in Porterﬁeld, 1986).
The most clearly established role for ADE in vivo exists for DENV
(reviewed in Halstead, 2003). Infection by any of the four serotypes of
DENV results in a febrile illness called dengue fever from which that
individual will typically recover and thereafter be immune to re-
infection by the same serotype of DENV. However, re-infection of that
same individual with a heterologous serotype of DENVmay result in a
more severe and potentially fatal clinical course (reviewed in
Halstead, 2002). While multiple host and viral factors likely
contribute to circumstances that lead to severe manifestations of
disease (Green and Rothman, 2006; Halstead, 2003), one possibility is
that antibodies raised during primary infection not only fail to protect
from secondary infection by a heterologous DENV serotype, but also
have the potential to enhance virus infection in vivo. The increased
Fig. 3. Factors that govern the neutralizing activity of anti-ﬂavivirus antibodies. Neutralization of ﬂavivirus infection is a multiple hit phenomenon that requires engagement of the
virion by antibody with a stoichiometry that exceeds a threshold. Whether an individual antibody can dock on the virion with a stoichiometry sufﬁcient to exceed this threshold
depends on its afﬁnity for viral antigens and the total number of accessible epitopes displayed on the average virion (shown schematically on the x-axis). Changes in epitope
accessibility signiﬁcantly impact the potency of neutralizing antibodies. The dynamic motion of DENV appears to regulate exposure of the A-strand epitope recognized by mAb
1A1D-2 at equilibrium, and explains the temperature-dependence of binding by this antibody. The process of virion maturation also impacts accessibility of epitopes bound by
neutralizing antibodies. Virion maturation reduces accessibility of several classes of antibodies to levels that no longer support neutralization. Interactions with the complement
protein C1q increase the potency of neutralizing antibodies, even those speciﬁc for poorly accessible determinants. C1q augments neutralization by decreasing the stoichiometric
threshold required for neutralization (shifted red dashed line, bottom).
Figure modiﬁed from (Pierson et al., 2008).
311K.A. Dowd, T.C. Pierson / Virology 411 (2011) 306–315risk of severe disease following primary infection of children of DENV-
immune mothers provides direct support for a role for antibody in
DENV pathogenesis (Kliks et al., 1988, 1989). In addition, enhanced
viremia has been observed following passive transfer of antibody in
primates (Goncalvez et al., 2007; Halstead, 1979), and two recent
reports describe the characterization of a murine model that
recapitulates some aspects of severe DENV, including the role of
antibody in augmenting infection in vivo (Balsitis et al., 2010;
Zellweger et al., 2010).
Virus neutralization and ADE are two phenomena related by the
number of antibodies bound to the virion (Morens et al., 1987; Pierson
et al., 2007). ADE occurs at concentrations of antibody bounded at an
upper limit by the stoichiometric threshold for neutralization, and at
lower concentrations by the minimal number of antibodies required
to support stable attachment of the virion to cells. Analysis of the
stoichiometric requirements for ADE of K562 cells that express the
Fcγ-receptor CD32 suggests that ~15 antibodies are required for
enhanced infection of WNV (Pierson et al., 2007). This provides a
useful perspective in which to evaluate the likelihood that antibodies
of known speciﬁcity will enhance infection. Potently neutralizing
antibodies support ADEwhen diluted past concentrations sufﬁcient toneutralize infection. For antibodies that recognize poorly accessible
determinants on the virion, which typically require full occupancy to
exceed the stoichiometric threshold for neutralization, even small
changes in the number of antibodies bound to the virion result in ADE.
Furthermore, antibodies that recognize infrequently displayed epi-
topes that do not support neutralization may enhance infection even
at saturation. Indeed, the enhancing properties of poorly neutralizing
prM-reactive antibodies can be observed over a wide range of
antibody concentrations (Beltramello et al., 2010; Dejnirattisai et al.,
2010).
The cell biology of ADE remains incompletely understood. ADE is
most readily observed on cell types that do not efﬁciently bind virus
particles. Antibodies complexed to virions may signiﬁcantly increase
the efﬁciency of virus attachment to cells through multivalent
interactions with Fc-receptors. ADE can be inhibited by antibodies
that block Fc-receptor engagement (Peiris et al., 1981), removal of
the antibody heavy chain (Zellweger et al., 2010), or deletion of the
N-linked sugar on IgG molecules required for interactions with Fcγ-
receptors (Balsitis et al., 2010; Goncalvez et al., 2007; Pierson et al.,
2007). The expression of cellular attachment factors on Fcγ-receptor
expressing cells markedly reduces the extent to which virus
312 K.A. Dowd, T.C. Pierson / Virology 411 (2011) 306–315infection may be enhanced in the presence of antibody (Boonnak et
al., 2008; Pierson et al., 2007). For example, immature dendritic cells
(DCs) do not appear to support ADE of DENV despite expressing
readily detectable Fcγ-receptors presumably because they express
the DENV attachment factor CD209 (DC-SIGN). In contrast, mature
DCs express reduced levels of CD209 and support ADE through Fcγ-
RIIa (Boonnak et al., 2008). In some instances, ADE may occur when
antibody molecules cross-react with both viral and cellular antigens.
DENV prM-speciﬁc antibodies were identiﬁed that were capable of
binding simultaneously to the virion and target cell, providing a Fcγ-
receptor-independent mechanism for internalization and infection
(Huang et al., 2006). A recent study demonstrated that 75% of mAbs
cloned from HIV-1-infected patients demonstrated polyreactive
speciﬁcities (Mouquet et al., 2010), however, whether ﬂavivirus-
speciﬁc antibodies with these properties are common remains
unclear.
While Fc-receptor-mediated uptake of DENV immune complexes
results in increased infection simply by increasing the number of
susceptible cells, recent studies have suggested signaling events that
occur following the ligation of Fc-receptors may be important for ADE
(Moi et al., 2010; Rodrigo et al., 2006), resulting in the inhibition of the
antiviral response and increased viral replication (intrinsic ADE).
Speciﬁcally, intrinsic ADE is thought to occur by two separate
mechanisms: 1) disruption of the RIG-I/MDA5 signaling cascade,
which in turn abrogates the type I IFN response, and 2) induction of
anti-inﬂammatory cytokines such as IL-10 coupled with suppression
of pro-inﬂammatory cytokines such as IL-12 and TNF-α (Boonnak
et al., 2008; Chareonsirisuthigul et al., 2007; Ubol et al., 2010).
Serum complement proteins increase the neutralizing activity of
antibodies via multiple mechanisms
While the engagement of virions by antibody has the potential to
directly neutralize infectivity, in the host these interactions occur in
the presence of serum proteins capable of modulating antibody
function. The complement system is a component of the innate
immune response capable of pathogen recognition and clearance that
is regulated by a complex cascade of cleavage events. The importance
of the complement system in viral immunity is highlighted by the
number and diversity of strategies evolved by viruses to antagonize it
(reviewed by Lambris et al., 2008). Activation of the complement
system occurs via three convergent pathways that ultimately lead to
the release of anaphylatoxins and chemotactic factors, deposition of
the opsonic complement protein C3b on the surface of the pathogen,
and the assembly of the membrane attack complex (MAC) capable of
pathogen lysis. The classical pathway of complement activation is
triggered by interactions between the complement protein C1q and
the Fc-portion of antibody molecules. C1q is a ~460 kDa multimeric
protein composed of six globular heads connected at the amino-
terminus by collagenous ﬂexible stalks (reviewed by Kishore and
Reid, 2000). While C1q can bind efﬁciently to a single pentameric IgM
molecule bound to the surface of a pathogen, the afﬁnity of
monomeric interactions with IgG is quite low. Efﬁcient interactions
with IgG molecules require multivalent interactions with antibody
molecules arrayed on the surface of the pathogen, and occur in an
isotype-dependent manner. In humans, IgG3 and IgG1 efﬁciently
interact with C1q (IgG3N IgG1), whereas C1q binding to IgG2 and IgG4
subclasses is very weak (the hierarchy of C1q binding to murine
antibodies is IgG2aN IgG2bN IgG1) (Leatherbarrow and Dwek, 1984;
Schumaker et al., 1976).
An understanding of the impact of complement on the potency of
antibodies has advanced considerably since the ﬁrst reports that heat-
labile factors in serum augment the neutralizing activity of antibodies.
Complement has been shown to increase the neutralization activity of
antibodies against many viruses, including ﬂaviviruses (Della-Porta
and Westaway, 1978). Several lines of evidence suggest that C1q issufﬁcient for enhancing the neutralizing activity of antibodies that
bind ﬂaviviruses (Mehlhop et al., 2009). Incubation of virion–antibody
complexes with fresh, but not heat-inactivated sera, results in more
efﬁcient neutralization in vitro; this effect is lost when serum
obtained from C1q- but not C3- or C5-deﬁcient mice is added to
neutralization experiments. The addition of recombinant C1q to
neutralization tests also results in increased neutralization in an
antibody isotype-dependent fashion. Together, these data suggest
that molecules in the complement cascade downstream of C1q
activation, including the formation of the MAC on virions, are not
required for enhanced neutralization of ﬂaviviruses. Studies of the
mechanism of complement-enhanced neutralization of inﬂuenza
virus reached similar conclusions (Feng et al., 2002). Neutralization
of the extracellular enveloped form of vaccinia virus (EV) by B5R-
speciﬁc antibodies was antibody isotype- and C1q-dependent, but
also required deposition of C3 (but not C5 activity) (Benhnia et al.,
2009).
C1q has the potential to directly increase the neutralizing activity
of antibodies through one or more mechanisms. Because C1q only
binds efﬁciently to multiple antibody molecules arrayed on the
surface of the virus particle (Kishore and Reid, 2000), C1q engage-
ment may increase the functional avidity of antibodies for the virion.
This would translate into enhanced neutralization via increased
antibody occupancy at any non-saturating concentration of antibody.
Multivalent C1q interactions also cross-link antibodies (and viral
proteins) on the surface of the virus particle together, whichmay have
signiﬁcant implications for the viral fusion machinery (Kaufmann
et al., 2009; Whiteman et al., 2010). Finally, the relatively large size of
C1q adds substantially to the bulk of antibody molecules bound to the
virion, which may increase neutralizing activity due to enhanced
steric effects.
Our studies with WNV suggest that C1q enhances antibody-
mediated neutralization by signiﬁcantly reducing the stoichiometric
requirements for neutralization (Mehlhop et al., 2009). Neutralization
of WNV can be controlled by manipulating the number of epitopes
displayed on the average virion using genetic approaches (Pierson
et al., 2007) or via changes in the maturation state of the virus particle
(Nelson et al., 2008), as discussed above. Reducing the number of
epitopes on the virion below the stoichiometric threshold required for
neutralization results in the appearance of a fraction of viruses
resistant to neutralization, even when incubated with saturating
concentrations of antibody. The addition of C1q to neutralization
studies dramatically reduced the size of this resistant fraction in an
isotype-dependent manner. In this context, C1q-mediated increases
in avidity are not sufﬁcient to explain this increase in neutralization
because all of the accessible epitopes on the virion are already bound
by saturating concentrations of antibody. Instead these results suggest
that C1q increases neutralizing activity through signiﬁcant changes in
the stoichiometric threshold for neutralization (Fig. 3). This effect
could be mimicked by the incubation of virion–antibody complexes
with Fab2 molecules speciﬁc for IgG, but not Fab fragments of the
same speciﬁcity incapable of bivalent interactions with antibodies
bound to the virion. These ﬁndings rule out a requirement for the very
large size of the C1q molecule, and suggest that cross-linking is
mechanistically important. A reduced stoichiometric requirement for
neutralization in the presence of C1q also provides a mechanism to
explain complement modulation of ADE (Mehlhop et al., 2007;
Yamanaka et al., 2008).
Toward understanding the complexities of the polyclonal
antibody response
Experiments withmAbs have yielded an increasingly sophisticated
understanding of the molecular mechanisms of ﬂavivirus neutraliza-
tion. A quantitative view of neutralization provides a framework to
deﬁne the functional and biochemical features of the most potently
313K.A. Dowd, T.C. Pierson / Virology 411 (2011) 306–315neutralizing antibodies, as well as those with the greatest potential to
enhance infection. The identiﬁcation of antibodies with therapeutic
value is an exciting practical product of these efforts (Morrey et al.,
2006). However, relatively little is known about the composition and
functional properties of antibodies elicited by ﬂavivirus infection. The
antibody response to infection is likely a polyclonal ensemble of
antibodies speciﬁc for structurally distinct epitopes on the virus
particle. While many of the most potent neutralizing antibodies bind
epitopes in E-DIII (Beasley and Barrett, 2002; Gromowski and Barrett,
2007; Oliphant et al., 2005), recent studies of human mAbs isolated
from immortalized B cells or the analysis of combinatorial libraries of
B cell donors suggest the repertoire of antibodies produced in vivo is
focused elsewhere (Beltramello et al., 2010; Dejnirattisai et al., 2010;
Throsby et al., 2006). Cross-reactive E-DII-reactive antibodies charac-
terized by limited neutralization activity are common. This conclusion
is supported by biochemical and serologic analysis of antibody
reactivity (Crill et al., 2009, 2007; Lai et al., 2008; Oliphant et al.,
2007). While it is possible that low concentrations of potently
neutralizing E-DIII-reactive antibodies could be functionally signiﬁ-
cant (Crill et al., 2009), two approaches suggest this is not the case.
Ablation of the DIII-LR epitope on WNV had little to no effect on the
neutralization titers of antibody in the sera of infected humans or
horses (Nelson et al., 2008; Oliphant et al., 2007; Sanchez et al., 2007).
In agreement, a recent study demonstrated that the depletion of the
DIII-reactive antibodies present in DENV-immune sera did not have a
signiﬁcant impact on neutralization when compared to non-depleted
sera (Wahala et al., 2009). While the analysis of the functional
interplay between components of the polyclonal antibody response is
at a relatively early stage, it holds great promise for the identiﬁcation
of epitopes associated with protective responses, insight into
circumstances that may contribute to augmented virus infection in
vivo, and more focused targets for immunization.
Acknowledgments
The authors thank Drs. Michael Diamond, Heather Hickman,
Thomas Kristie and members of our laboratory for helpful discussions
and critical comments on this manuscript. This work was supported
by the intramural program of the National Institute of Allergy and
Infectious Disease.
References
Aaskov, J.G., Williams, L., Fletcher, J., Hay, R., 1988. Failure of a dengue 1 sub-unit
vaccine to protect mice against a lethal dengue virus infection. Am. J. Trop. Med.
Hyg. 39 (5), 511–518.
Balsitis, S.J., Williams, K.L., Lachica, R., Flores, D., Kyle, J.L., Mehlhop, E., Johnson, S.,
Diamond, M.S., Beatty, P.R., Harris, E., 2010. Lethal antibody enhancement of
dengue disease in mice is prevented by Fc modiﬁcation. PLoS Pathog. 6 (2),
e1000790.
Barrett, A.D., Teuwen, D.E., 2009. Yellow fever vaccine — how does it work and why do
rare cases of serious adverse events take place? Curr. Opin. Immunol. 21 (3),
308–313.
Beasley, D.W., Barrett, A.D., 2002. Identiﬁcation of neutralizing epitopes within
structural domain III of the West Nile virus envelope protein. J. Virol. 76 (24),
13097–13100.
Beltramello, M., Williams, K.L., Simmons, C.P., Macagno, A., Simonelli, L., Quyen, N.T.,
Sukupolvi-Petty, S., Navarro-Sanchez, E., Young, P.R., de Silva, A.M., Rey, F.A.,
Varani, L., Whitehead, S.S., Diamond, M.S., Harris, E., Lanzavecchia, A., Sallusto, F.,
2010. The human immune response to dengue virus is dominated by highly cross-
reactive antibodies endowed with neutralizing and enhancing activity. Cell Host
Microbe 8 (3), 271–283.
Benhnia, M.R., McCausland, M.M., Laudenslager, J., Granger, S.W., Rickert, S., Koriazova,
L., Tahara, T., Kubo, R.T., Kato, S., Crotty, S., 2009. Heavily isotype-dependent
protective activities of human antibodies against vaccinia virus extracellular virion
antigen B5. J. Virol. 83 (23), 12355–12367.
Boehr, D.D., Wright, P.E., 2008. Biochemistry. How do proteins interact? Science 320
(5882), 1429–1430.
Boonnak, K., Slike, B.M., Burgess, T.H., Mason, R.M., Wu, S.J., Sun, P., Porter, K., Rudiman,
I.F., Yuwono, D., Puthavathana, P., Marovich, M.A., 2008. Role of dendritic cells in
antibody-dependent enhancement of dengue virus infection. J. Virol. 82 (8),
3939–3951.Booy, F.P., Roden, R.B., Greenstone, H.L., Schiller, J.T., Trus, B.L., 1998. Two antibodies
that neutralize papillomavirus by different mechanisms show distinct binding
patterns at 13 A resolution. J. Mol. Biol. 281 (1), 95–106.
Bothner, B., Dong, X.F., Bibbs, L., Johnson, J.E., Siuzdak, G., 1998. Evidence of viral capsid
dynamics using limited proteolysis and mass spectrometry. J. Biol. Chem. 273 (2),
673–676.
Brien, J.D., Austin, S.K., Sukupolvi-Petty, S., O'Brien, K.M., Johnson, S., Fremont, D.H.,
Diamond, M.S., 2010. Genotype speciﬁc neutralization and protection by antibodies
against dengue virus type 3. J. Virol. 84 (20), 10603–10643.
Burnet, F.M., Keogh, E.V., Lush, D., 1937. The immunological reactions of the ﬁlterable
viruses. Aust. J. Exp. Biol. Med. Sci. 15, 227–368.
Burton, D.R., 2002. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2 (9), 706–713.
Burton, D.R., Saphire, E.O., Parren, P.W., 2001. A model for neutralization of viruses
based on antibody coating of the virion surface. Curr. Top. Microbiol. Immunol. 260,
109–143.
Chareonsirisuthigul, T., Kalayanarooj, S., Ubol, S., 2007. Dengue virus (DENV)
antibody-dependent enhancement of infection upregulates the production of
anti-inﬂammatory cytokines, but suppresses anti-DENV free radical and pro-
inﬂammatory cytokine production, in THP-1 cells. J. Gen. Virol. 88 (Pt 2),
365–375.
Cherrier, M.V., Kaufmann, B., Nybakken, G.E., Lok, S.M., Warren, J.T., Chen, B.R., Nelson,
C.A., Kostyuchenko, V.A., Holdaway, H.A., Chipman, P.R., Kuhn, R.J., Diamond, M.S.,
Rossmann, M.G., Fremont, D.H., 2009. Structural basis for the preferential
recognition of immature ﬂaviviruses by a fusion-loop antibody. EMBO J. 28 (20),
3269–3276.
Crill, W.D., Roehrig, J.T., 2001. Monoclonal antibodies that bind to domain III of dengue
virus E glycoprotein are the most efﬁcient blockers of virus adsorption to Vero cells.
J. Virol. 75 (16), 7769–7773.
Crill, W.D., Trainor, N.B., Chang, G.J., 2007. A detailed mutagenesis study of ﬂavivirus
cross-reactive epitopes using West Nile virus-like particles. J. Gen. Virol. 88 (Pt 4),
1169–1174.
Crill, W.D., Hughes, H.R., Delorey, M.J., Chang, G.J., 2009. Humoral immune responses of
dengue fever patients using epitope-speciﬁc serotype-2 virus-like particle
antigens. PLoS ONE 4 (4), e4991.
Davis, C.W., Nguyen, H.Y., Hanna, S.L., Sanchez, M.D., Doms, R.W., Pierson, T.C., 2006.
West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular
attachment and infection. J. Virol. 80 (3), 1290–1301.
Dejnirattisai, W., Jumnainsong, A., Onsirisakul, N., Fitton, P., Vasanawathana, S.,
Limpitikul, W., Puttikhunt, C., Edwards, C., Duangchinda, T., Supasa, S., Chawan-
suntati, K., Malasit, P., Mongkolsapaya, J., Screaton, G., 2010. Cross-reacting
antibodies enhance dengue virus infection in humans. Science 328 (5979),
745–748.
Della-Porta, A.J., Westaway, E.G., 1978. A multi-hit model for the neutralization of
animal viruses. J. Gen. Virol. 38 (1), 1–19.
Dulbecco, R., Vogt, M., Strickland, A.G., 1956. A study of the basic aspects of
neutralization of two animal viruses, western equine encephalitis virus and
poliomyelitis virus. Virology 2 (2), 162–205.
Elshuber, S., Allison, S.L., Heinz, F.X., Mandl, C.W., 2003. Cleavage of protein prM is
necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J. Gen.
Virol. 84 (Pt 1), 183–191.
Feng, J.Q., Mozdzanowska, K., Gerhard, W., 2002. Complement component C1q
enhances the biological activity of inﬂuenza virus hemagglutinin-speciﬁc anti-
bodies depending on their ﬁne antigen speciﬁcity and heavy-chain isotype. J. Virol.
76 (3), 1369–1378.
Flamand, A., Raux, H., Gaudin, Y., Ruigrok, R.W., 1993. Mechanisms of rabies virus
neutralization. Virology 194 (1), 302–313.
Gollins, S.W., Porterﬁeld, J.S., 1986. A new mechanism for the neutralization of
enveloped viruses by antiviral antibody. Nature 321 (6067), 244–246.
Goncalvez, A.P., Engle, R.E., St Claire, M., Purcell, R.H., Lai, C.J., 2007. Monoclonal
antibody-mediated enhancement of dengue virus infection in vitro and in vivo and
strategies for prevention. Proc. Natl Acad. Sci. USA 104 (22), 9422–9427.
Green, S., Rothman, A., 2006. Immunopathological mechanisms in dengue and dengue
hemorrhagic fever. Curr. Opin. Infect. Dis. 19 (5), 429–436.
Gromowski, G.D., Barrett, A.D., 2007. Characterization of an antigenic site that contains
a dominant, type-speciﬁc neutralization determinant on the envelope protein
domain III (ED3) of dengue 2 virus. Virology 366 (2), 349–360.
Gromowski, G.D., Barrett, N.D., Barrett, A.D., 2008. Characterization of dengue complex-
speciﬁc neutralizing epitopes on the envelope protein domain III of dengue 2 virus. J.
Virol. 82 (17), 8828–8837.
Gromowski, G.D., Roehrig, J.T., Diamond, M.S., Lee, J.C., Pitcher, T.J., Barrett, A.D., 2010.
Mutations of an antibody binding energy hot spot on domain III of the dengue 2
envelope glycoprotein exploited for neutralization escape. Virology 407 (2), 237–246.
Guirakhoo, F., Heinz, F.X., Mandl, C.W., Holzmann, H., Kunz, C., 1991. Fusion activity of
ﬂaviviruses: comparison of mature and immature (prM-containing) tick-borne
encephalitis virions. J. Gen. Virol. 72 (Pt 6), 1323–1329.
Guirakhoo, F., Bolin, R.A., Roehrig, J.T., 1992. The Murray Valley encephalitis virus prM
protein confers acid resistance to virus particles and alters the expression of
epitopes within the R2 domain of E glycoprotein. Virology 191 (2), 921–931.
Guy, B., Guirakhoo, F., Barban, V., Higgs, S., Monath, T.P., Lang, J., 2010. Preclinical and
clinical development of YFV 17D-based chimeric vaccines against dengue, West
Nile and Japanese encephalitis viruses. Vaccine 28 (3), 632–649.
Halstead, S.B., 1979. In vivo enhancement of dengue virus infection in rhesus monkeys
by passively transferred antibody. J. Infect. Dis. 140 (4), 527–533.
Halstead, S.B., 2002. Dengue. Curr. Opin. Infect. Dis. 15 (5), 471–476.
Halstead, S.B., 2003. Neutralization and antibody-dependent enhancement of dengue
viruses. Adv. Virus Res. 60, 421–467.
314 K.A. Dowd, T.C. Pierson / Virology 411 (2011) 306–315Halstead, S.B., O'Rourke, E.J., 1977. Antibody-enhanced dengue virus infection in
primate leukocytes. Nature 265 (5596), 739–741.
Halstead, S.B., Thomas, S.J., 2010. Japanese encephalitis: new options for active
immunization. Clin. Infect. Dis. 50 (8), 1155–1164.
Harrison, S.C., 2008. Viral membrane fusion. Nat. Struct. Mol. Biol. 15 (7), 690–698.
Hawkes, R.A., 1964. Enhancement of the infectivity of arboviruses by speciﬁc antisera
produced in domestic fowls. Aust. J. Exp. Biol. Med. Sci. 42, 465–482.
He, R.T., Innis, B.L., Nisalak, A., Usawattanakul, W., Wang, S., Kalayanarooj, S., Anderson,
R., 1995. Antibodies that block virus attachment to Vero cells are a major
component of the human neutralizing antibody response against dengue virus type
2. J. Med. Virol. 45 (4), 451–461.
Heinz, F.X., Stiasny, K., Puschner-Auer, G., Holzmann, H., Allison, S.L., Mandl, C.W., Kunz,
C., 1994. Structural changes and functional control of the tick-borne encephalitis
virus glycoprotein E by the heterodimeric association with protein prM. Virology
198 (1), 109–117.
Heinz, F.X., Holzmann, H., Essl, A., Kundi, M., 2007. Field effectiveness of vaccination
against tick-borne encephalitis. Vaccine 25 (43), 7559–7567.
Huang, K.J., Yang, Y.C., Lin, Y.S., Huang, J.H., Liu, H.S., Yeh, T.M., Chen, S.H., Liu, C.C., Lei, H.Y.,
2006. The dual-speciﬁc binding of dengue virus and target cells for the antibody-
dependent enhancement of dengue virus infection. J. Immunol. 176 (5), 2825–2832.
Icenogle, J., Shiwen, H., Duke, G., Gilbert, S., Rueckert, R., Anderegg, J., 1983.
Neutralization of poliovirus by a monoclonal antibody: kinetics and stoichiometry.
Virology 127 (2), 412–425.
Johnson, J.E., 2003. Virus particle dynamics. Adv. Protein Chem. 64, 197–218.
Junjhon, J., Edwards, T.J., Utaipat, U., Bowman, V.D., Holdaway, H.A., Zhang, W.,
Keelapang, P., Puttikhunt, C., Perera, R., Chipman, P.R., Kasinrerk, W., Malasit, P.,
Kuhn, R.J., Sittisombut, N., 2010. Inﬂuence of pr-M cleavage on the heterogeneity of
extracellular dengue virus particles. J. Virol. 84 (16), 8353–8358.
Kaufman, B.M., Summers, P.L., Dubois, D.R., Cohen, W.H., Gentry, M.K., Timchak, R.L.,
Burke, D.S., Eckels, K.H., 1989. Monoclonal antibodies for dengue virus prM
glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 41
(5), 576–580.
Kaufmann, B., Nybakken, G.E., Chipman, P.R., Zhang, W., Diamond, M.S., Fremont, D.H.,
Kuhn, R.J., Rossmann, M.G., 2006. West Nile virus in complex with the Fab fragment
of a neutralizing monoclonal antibody. Proc. Natl Acad. Sci. USA 103 (33),
12400–12404.
Kaufmann, B., Chipman, P.R., Holdaway, H.A., Johnson, S., Fremont, D.H., Kuhn, R.J.,
Diamond, M.S., Rossmann, M.G., 2009. Capturing a ﬂavivirus pre-fusion interme-
diate. PLoS Pathog. 5 (11), e1000672.
Kaufmann, B., Vogt, M.R., Goudsmit, J., Holdaway, H.A., Aksyuk, A.A., Chipman, P.R.,
Kuhn, R.J., Diamond, M.S., Rossmann, M.G., 2010. Neutralization of West Nile virus
by cross-linking of its surface proteins with Fab fragments of the human
monoclonal antibody CR4354. Proc. Natl Acad. Sci. USA 107 (44), 18950–18955.
Kiermayr, S., Stiasny, K., Heinz, F.X., 2009. Impact of quaternary organization on the
antigenic structureof the tick-borneencephalitis virus envelope glycoprotein E. J. Virol.
83 (17), 8482–8491.
Kishore, U., Reid, K.B., 2000. C1q: structure, function, and receptors. Immunopharma-
cology 49 (1–2), 159–170.
Klasse, P.J., Burton, D.R., 2007. Antibodies toWest Nile virus: a double-edged sword. Cell
Host Microbe 1 (2), 87–89.
Klasse, P.J., Sattentau, Q.J., 2002. Occupancy and mechanism in antibody-mediated
neutralization of animal viruses. J. Gen. Virol. 83 (Pt 9), 2091–2108.
Klein, J.S., Gnanapragasam, P.N., Galimidi, R.P., Foglesong, C.P., West Jr., A.P., Bjorkman,
P.J., 2009. Examination of the contributions of size and avidity to the neutralization
mechanisms of the anti-HIV antibodies b12 and 4E10. Proc. Natl Acad. Sci. USA 106
(18), 7385–7390.
Kliks, S.C., Nimmanitya, S., Nisalak, A., Burke, D.S., 1988. Evidence that maternal dengue
antibodies are important in the development of dengue hemorrhagic fever in
infants. Am. J. Trop. Med. Hyg. 38 (2), 411–419.
Kliks, S.C., Nisalak, A., Brandt, W.E., Wahl, L., Burke, D.S., 1989. Antibody-dependent
enhancement of dengue virus growth in human monocytes as a risk factor for
dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40 (4), 444–451.
Kuhn, R.J., Zhang, W., Rossmann, M.G., Pletnev, S.V., Corver, J., Lenches, E., Jones, C.T.,
Mukhopadhyay, S., Chipman, P.R., Strauss, E.G., Baker, T.S., Strauss, J.H., 2002.
Structure of dengue virus: implications for ﬂavivirus organization, maturation, and
fusion. Cell 108 (5), 717–725.
Lai, C.Y., Tsai, W.Y., Lin, S.R., Kao, C.L., Hu, H.P., King, C.C., Wu, H.C., Chang, G.J., Wang,
W.K., 2008. Antibodies to envelope glycoprotein of dengue virus during the natural
course of infection are predominantly cross-reactive and recognize epitopes
containing highly conserved residues at the fusion loop of domain II. J. Virol. 82
(13), 6631–6643.
Lambris, J.D., Ricklin, D., Geisbrecht, B.V., 2008. Complement evasion by human
pathogens. Nat. Rev. Microbiol. 6 (2), 132–142.
Leatherbarrow, R.J., Dwek, R.A., 1984. Binding of complement subcomponent C1q tomouse
IgG1, IgG2a and IgG2b: a novel C1q binding assay. Mol. Immunol. 21 (4), 321–327.
Lewis, J.K., Bothner, B., Smith, T.J., Siuzdak, G., 1998. Antiviral agent blocks breathing of
the common cold virus. Proc. Natl Acad. Sci. USA 95 (12), 6774–6778.
Li, Q., Yafal, A.G., Lee, Y.M., Hogle, J., Chow, M., 1994. Poliovirus neutralization by
antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of
these sequences at physiological temperature. J. Virol. 68 (6), 3965–3970.
Li, L., Lok, S.M., Yu, I.M., Zhang, Y., Kuhn, R.J., Chen, J., Rossmann, M.G., 2008. The
ﬂavivirus precursor membrane-envelope protein complex: structure and matura-
tion. Science 319 (5871), 1830–1834.
Lindenbach, B.D., Thiel, H.J., Rice, C.M., 2007. In: Knipe, D.M., Howley, P.M. (Eds.),
Flaviviridae: The Viruses and Their Replication, 5th ed. : Fields Virology, Vol. 1.
Lippincott-Williams & Wilkins, Philadelphia, pp. 1101–1152. 2 vols.Lok, S.M., Kostyuchenko, V., Nybakken, G.E., Holdaway, H.A., Battisti, A.J., Sukupolvi-
Petty, S., Sedlak, D., Fremont, D.H., Chipman, P.R., Roehrig, J.T., Diamond, M.S., Kuhn,
R.J., Rossmann, M.G., 2008. Binding of a neutralizing antibody to dengue virus alters
the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15 (3), 312–317.
Mandel, B., 1976. Neutralization of poliovirus: a hypothesis to explain the mechanism
and the one-hit character of the neutralization reaction. Virology 69 (2), 500–510.
Mandl, C.W., Guirakhoo, F., Holzmann, H., Heinz, F.X., Kunz, C., 1989. Antigenic
structure of the ﬂavivirus envelope protein E at the molecular level, using tick-
borne encephalitis virus as a model. J. Virol. 63 (2), 564–571.
Mehlhop, E., Ansarah-Sobrinho, C., Johnson, S., Engle, M., Fremont, D.H., Pierson, T.C.,
Diamond, M.S., 2007. Complement protein C1q inhibits antibody-dependent
enhancement of ﬂavivirus infection in an IgG subclass-speciﬁc manner. Cell Host
Microbe 2 (6), 417–426.
Mehlhop, E., Nelson, S., Jost, C.A., Gorlatov, S., Johnson, S., Fremont, D.H., Diamond, M.S.,
Pierson, T.C., 2009. Complement protein C1q reduces the stoichiometric threshold for
antibody-mediatedneutralization ofWest Nile virus. CellHostMicrobe 6 (4), 381–391.
Moi, M.L., Lim, C.K., Takasaki, T., Kurane, I., 2010. Involvement of the Fc gamma receptor
IIA cytoplasmic domain in antibody-dependent enhancement of dengue virus
infection. J. Gen. Virol. 91 (Pt 1), 103–111.
Morens, D.M., Halstead, S.B., Marchette, N.J., 1987. Proﬁles of antibody-dependent
enhancement of dengue virus type 2 infection. Microb. Pathog. 3 (4), 231–237.
Morrey, J.D., Siddharthan, V., Olsen, A.L., Roper, G.Y., Wang, H., Baldwin, T.J., Koenig, S.,
Johnson, S., Nordstrom, J.L., Diamond, M.S., 2006. Humanized monoclonal antibody
against West Nile virus envelope protein administered after neuronal infection
protects against lethal encephalitis in hamsters. J. Infect. Dis. 194 (9), 1300–1308.
Mouquet, H., Scheid, J.F., Zoller, M.J., Krogsgaard, M., Ott, R.G., Shukair, S., Artyomov,
M.N., Pietzsch, J., Connors, M., Pereyra, F., Walker, B.D., Ho, D.D., Wilson, P.C.,
Seaman, M.S., Eisen, H.N., Chakraborty, A.K., Hope, T.J., Ravetch, J.V., Wardemann,
H., Nussenzweig, M.C., 2010. Polyreactivity increases the apparent afﬁnity of anti-
HIV antibodies by heteroligation. Nature 467 (7315), 591–595.
Mukhopadhyay, S., Kim, B.S., Chipman, P.R., Rossmann, M.G., Kuhn, R.J., 2003. Structure
of West Nile virus. Science 302 (5643), 248.
Mukhopadhyay, S., Kuhn, R.J., Rossmann, M.G., 2005. A structural perspective of the
ﬂavivirus life cycle. Nat. Rev. Microbiol. 3 (1), 13–22.
Nelson, S., Jost, C.A., Xu, Q., Ess, J., Martin, J.E., Oliphant, T., Whitehead, S.S., Durbin, A.P.,
Graham, B.S., Diamond, M.S., Pierson, T.C., 2008. Maturation of West Nile virus
modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 4 (5),
e1000060.
Nimmerjahn, F., Ravetch, J.V., 2008. Fcgamma receptors as regulators of immune
responses. Nat. Rev. Immunol. 8 (1), 34–47.
Nybakken, G.E., Oliphant, T., Johnson, S., Burke, S., Diamond, M.S., Fremont, D.H., 2005.
Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature
437 (7059), 764–769.
Oliphant, T., Engle, M., Nybakken, G.E., Doane, C., Johnson, S., Huang, L., Gorlatov, S.,
Mehlhop, E., Marri, A., Chung, K.M., Ebel, G.D., Kramer, L.D., Fremont, D.H.,
Diamond, M.S., 2005. Development of a humanized monoclonal antibody with
therapeutic potential against West Nile virus. Nat. Med. 11 (6), 522–530.
Oliphant, T., Nybakken, G.E., Engle, M., Xu, Q., Nelson, C.A., Sukupolvi-Petty, S., Marri, A.,
Lachmi, B.E., Olshevsky, U., Fremont, D.H., Pierson, T.C., Diamond, M.S., 2006.
Antibody recognition and neutralization determinants on domains I and II of West
Nile virus envelope protein. J. Virol. 80 (24), 12149–12159.
Oliphant, T., Nybakken, G.E., Austin, S.K., Xu, Q., Bramson, J., Loeb, M., Throsby, M.,
Fremont, D.H., Pierson, T.C., Diamond, M.S., 2007. Induction of epitope-speciﬁc
neutralizing antibodies against West Nile virus. J. Virol. 81 (21), 11828–11839.
Parren, P.W., Burton, D.R., 2001. The antiviral activity of antibodies in vitro and in vivo.
Adv. Immunol. 77, 195–262.
Peiris, J.S., Gordon, S., Unkeless, J.C., Porterﬁeld, J.S., 1981. Monoclonal anti-Fc receptor
IgG blocks antibody enhancement of viral replication in macrophages. Nature 289
(5794), 189–191.
Pierson, T.C., Xu, Q., Nelson, S., Oliphant, T., Nybakken, G.E., Fremont, D.H., Diamond,
M.S., 2007. The stoichiometry of antibody-mediated neutralization and enhance-
ment of West Nile virus infection. Cell Host Microbe 1 (2), 135–145.
Pierson, T.C., Fremont, D.H., Kuhn, R.J., Diamond, M.S., 2008. Structural insights into the
mechanisms of antibody-mediated neutralization of ﬂavivirus infection: implica-
tions for vaccine development. Cell Host Microbe 4 (3), 229–238.
Porterﬁeld, J.S., 1986. Antibody-dependent enhancement of viral infectivity. Adv. Virus
Res. 31, 335–355.
Roden, R.B., Weissinger, E.M., Henderson, D.W., Booy, F., Kirnbauer, R., Mushinski, J.F.,
Lowy, D.R., Schiller, J.T., 1994. Neutralization of bovine papillomavirus by
antibodies to L1 and L2 capsid proteins. J. Virol. 68 (11), 7570–7574.
Rodenhuis-Zybert, I.A., van der Schaar, H.M., da Silva Voorham, J.M., van der Ende-
Metselaar, H., Lei, H.Y., Wilschut, J., Smit, J.M., 2010. Immature dengue virus: a
veiled pathogen? PLoS Pathog. 6 (1), e1000718.
Rodrigo, W.W., Jin, X., Blackley, S.D., Rose, R.C., Schlesinger, J.J., 2006. Differential
enhancement of dengue virus immune complex infectivity mediated by signaling-
competent and signaling-incompetent human Fcgamma RIA (CD64) or Fcgam-
maRIIA (CD32). J. Virol. 80 (20), 10128–10138.
Roehrig, J.T., 2003. Antigenic structure ofﬂavivirus proteins. Adv. Virus Res. 59, 141–175.
Roehrig, J.T., Bolin, R.A., Kelly, R.G., 1998. Monoclonal antibodymapping of the envelope
glycoprotein of the dengue 2 virus, Jamaica. Virology 246 (2), 317–328.
Roehrig, J.T., Staudinger, L.A., Hunt, A.R., Mathews, J.H., Blair, C.D., 2001. Antibody
prophylaxis and therapy for ﬂavivirus encephalitis infections. Ann. NY Acad. Sci.
951, 286–297.
Sanchez, M.D., Pierson, T.C., Degrace, M.M., Mattei, L.M., Hanna, S.L., Del Piero, F., Doms,
R.W., 2007. The neutralizing antibody response against West Nile virus in naturally
infected horses. Virology 359 (2), 336–348.
315K.A. Dowd, T.C. Pierson / Virology 411 (2011) 306–315Sawyer, L.A., 2000. Antibodies for the prevention and treatment of viral diseases.
Antivir. Res. 47 (2), 57–77.
Schumaker, V.N., Calcott, M.A., Spiegelberg, H.L., Muller-Eberhard, H.J., 1976. Ultra-
centifuge studies of the binding of IgG of different subclasses to the Clq subunit of
the ﬁrst component of complement. Biochemistry 15 (23), 5175–5181.
Shepherd, C.M., Borelli, I.A., Lander, G., Natarajan, P., Siddavanahalli, V., Bajaj, C.,
Johnson, J.E., Brooks III, C.L., Reddy, V.S., 2006. VIPERdb: a relational database for
structural virology. Nucleic Acids Res. 34, D386–D389 Database issue.
Shrestha, B., Brien, J.D., Sukupolvi-Petty, S., Austin, S.K., Edeling, M.A., Kim, T., O'Brien,
K.M., Nelson, C.A., Johnson, S., Fremont, D.H., Diamond, M.S., 2010. The
development of therapeutic antibodies that neutralize homologous and heterol-
ogous genotypes of dengue virus type 1. PLoS Pathog. 6 (4), e1000823.
Stiasny, K., Kiermayr, S., Holzmann, H., Heinz, F.X., 2006. Cryptic properties of a cluster
of dominant ﬂavivirus cross-reactive antigenic sites. J. Virol. 80 (19), 9557–9568.
Stiasny, K., Brandler, S., Kossl, C., Heinz, F.X., 2007. Probing the ﬂavivirus membrane
fusion mechanism by using monoclonal antibodies. J. Virol. 81 (20), 11526–11531.
Sukupolvi-Petty, S., Austin, S.K., Purtha,W.E., Oliphant, T., Nybakken, G.E., Schlesinger, J.J.,
Roehrig, J.T., Gromowski, G.D., Barrett, A.D., Fremont,D.H., Diamond,M.S., 2007. Type-
and subcomplex-speciﬁc neutralizing antibodies against domain III of dengue virus
type 2 envelope protein recognize adjacent epitopes. J. Virol. 81 (23), 12816–12826.
Sukupolvi-Petty, S., Austin, S.K., Engle, M., Brien, J.D., Dowd, K.A., Williams, K.L.,
Johnson, S., Rico-Hesse, R., Harris, E., Pierson, T.C., Fremont, D.H., Diamond, M.S.,
2010. Structure and function analysis of therapeutic monoclonal antibodies against
dengue virus type 2. J. Virol. 84 (18), 9227–9239.
Thompson, B.S., Moesker, B., Smit, J.M., Wilschut, J., Diamond, M.S., Fremont, D.H., 2009.
A therapeutic antibody against West Nile virus neutralizes infection by blocking
fusion within endosomes. PLoS Pathog. 5 (5), e1000453.
Throsby, M., Geuijen, C., Goudsmit, J., Bakker, A.Q., Korimbocus, J., Kramer, R.A.,
Clijsters-van der Horst, M., de Jong, M., Jongeneelen, M., Thijsse, S., Smit, R., Visser,
T.J., Bijl, N., Marissen, W.E., Loeb, M., Kelvin, D.J., Preiser, W., ter Meulen, J., de Kruif,
J., 2006. Isolation and characterization of human monoclonal antibodies from
individuals infected with West Nile Virus. J. Virol. 80 (14), 6982–6992.
Ubol, S., Phuklia, W., Kalayanarooj, S., Modhiran, N., 2010. Mechanisms of immune
evasion induced by a complex of dengue virus and preexisting enhancing
antibodies. J. Infect. Dis. 201 (6), 923–935.Vazquez, S., Guzman, M.G., Guillen, G., Chinea, G., Perez, A.B., Pupo, M., Rodriguez, R.,
Reyes, O., Garay, H.E., Delgado, I., Garcia, G., Alvarez, M., 2002. Immune response
to synthetic peptides of dengue prM protein. Vaccine 20 (13–14), 1823–1830.
Vogt, M.R., Moesker, B., Goudsmit, J., Jongeneelen, M., Austin, S.K., Oliphant, T., Nelson,
S., Pierson, T.C., Wilschut, J., Throsby, M., Diamond, M.S., 2009. Human monoclonal
antibodies induced by natural infection against West Nile virus neutralize at a post-
attachment step. J. Virol. 83 (13), 6494–6507.
Wahala, W.M., Kraus, A.A., Haymore, L.B., Accavitti-Loper, M.A., de Silva, A.M., 2009.
Dengue virus neutralization by human immune sera: role of envelope protein
domain III-reactive antibody. Virology 392 (1), 103–113.
Wahala, W.M., Donaldson, E.F., de Alwis, R., Accavitti-Loper, M.A., Baric, R.S., de Silva,
A.M., 2010. Natural strain variation and antibody neutralization of dengue serotype
3 viruses. PLoS Pathog. 6 (3), e1000821.
Whitehead, S.S., Blaney, J.E., Durbin, A.P., Murphy, B.R., 2007. Prospects for a dengue
virus vaccine. Nat. Rev. Microbiol. 5 (7), 518–528.
Whiteman, M.C., Li, L., Wicker, J.A., Kinney, R.M., Huang, C., Beasley, D.W., Chung, K.M.,
Diamond, M.S., Solomon, T., Barrett, A.D., 2010. Development and characterization
of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for
West Nile virus. Vaccine 28 (4), 1075–1083.
Witz, J., Brown, F., 2001. Structural dynamics, an intrinsic property of viral capsids. Arch.
Virol. 146 (12), 2263–2274.
Yamanaka, A., Kosugi, S., Konishi, E., 2008. Infection-enhancing and -neutralizing
activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are
controlled by complement levels. J. Virol. 82 (2), 927–937.
Yu, I.M., Zhang, W., Holdaway, H.A., Li, L., Kostyuchenko, V.A., Chipman, P.R., Kuhn, R.J.,
Rossmann, M.G., Chen, J., 2008. Structure of the immature dengue virus at low pH
primes proteolytic maturation. Science 319 (5871), 1834–1837.
Zellweger, R.M., Prestwood, T.R., Shresta, S., 2010. Enhanced infection of liver sinusoidal
endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell
Host Microbe 7 (2), 128–139.
Zhang, Y., Corver, J., Chipman, P.R., Zhang, W., Pletnev, S.V., Sedlak, D., Baker, T.S.,
Strauss, J.H., Kuhn, R.J., Rossmann, M.G., 2003. Structures of immature ﬂavivirus
particles. EMBO J. 22 (11), 2604–2613.
Zhang, Y., Kaufmann, B., Chipman, P.R., Kuhn, R.J., Rossmann, M.G., 2007. Structure of
immature West Nile virus. J. Virol. 81 (11), 6141–6145.
